| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 10/21/2004 | US20040209326 Immunoglobulin for use in detection and prevention staphylococcus infections |
| 10/21/2004 | US20040209310 Ligands that bind to the amyloid-beta precursor peptide and related molecules and uses thereof |
| 10/21/2004 | US20040209306 Novel proteins in enteroaggregative escherichia coli (EAEC) useful for diagnosis and therapy of EAEC infections |
| 10/21/2004 | US20040209296 Using transcription factor inhibitors and human leukocyte antigen antibodies to prevent and treatcell proliferfative disorders; genetic vaccines and antitumor agents |
| 10/21/2004 | US20040208920 injectable liposomal composition for delivery of large amounts of water-soluble substance comprises a plurality of liposomal vesicles having a high weight ratio of lipid to encapsulated water-soluble substance which is distributed over the liposomal vesicles; high efficiency of encapsulation |
| 10/21/2004 | US20040208919 Vaccination against prion diseases |
| 10/21/2004 | US20040208901 Methods for preventing cattle reproductive diseases |
| 10/21/2004 | US20040208900 mutant rabies virus comprising a rabies virus N protein that is not phosphorylated; central nervous system (CNS) |
| 10/21/2004 | US20040208899 Apparatus for diagnosis and treatment of swine infertility and respiratory virus (SIRS) syndrome; vaccines |
| 10/21/2004 | US20040208898 administering a vaccine comprising a low dose of each of diphtheria toxoid (D), tetanus toxoid (T), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (69K); vaccine maintains an ability to prevent pertussis while showing low reactogenicity |
| 10/21/2004 | US20040208897 microbial cell comprising an Environmentally Limited Viability System made of an essential and a lethal gene ; cell is viable in a permissive environment and non-viable or temporarily viable in a non-permissive environment |
| 10/21/2004 | US20040208895 administering HETEROLOGOUS GENE PRODUCTS IN HOST CELL SYSTEMS AND/OR TO RESCUE NEGATIVE STRAND RNA RECOMBINANT VIRUSES |
| 10/21/2004 | US20040208894 compositions with dead E. coli; for treating or preventing undesirable allergic reactions and anaphylactic allergic reactions to allergens in a subject. rectal administration |
| 10/21/2004 | US20040208890 secreted Chlamydia polypeptides expressed by a Gram-negative bacterial strain and secreted by the type III secretion pathway; vaccination, and diagnostic uses |
| 10/21/2004 | US20040208888 Method of and compositions for immunization with the pseudomonas v antigen |
| 10/21/2004 | US20040208884 Administering construct in conjugated or unconjugated form and in combination with immunogenic carrier to induce antibodies; anticarcinogenic agents |
| 10/21/2004 | US20040208882 Ltb4 as vaccine adjuvant |
| 10/21/2004 | US20040208878 Treatment of acute lung injury, fibrosis and metastasis with antagonists of alphabetav6 |
| 10/21/2004 | US20040208876 Monoclonal antibodies to hepatocyte growth factor |
| 10/21/2004 | US20040208874 Treating a tumor necrosis factor (TNF)- alpha mediated disease by administering TNF- alpha inhibitor and a B7gene or protein inhibitor and/or a CD28/antigen/ inhibitor; antiinflammatory agents; arthritis, autoimmune diseases, inflammatory bowel disease, psoriasis, lupus, graft versus host disease |
| 10/21/2004 | US20040208870 Stabilized high concentration anti-integrin alphanubeta3 antibody formulations |
| 10/21/2004 | US20040208869 Preventing or treating an autoimmune disease, bone or metabolic disorder associated with aberrant expression of integrin alpha v beta 3 by administering an antibody or antibody fragment that immunospecifically binds to integrin alpha v beta 3; antiinflammatory agents |
| 10/21/2004 | US20040208868 Antibody that binds to phosphatidyl serine comprising a CDR of the monoclonal antibody 3G4 produced by hybridoma; anticarcinogenic, antitumor, and viricidal agents; angiogenesis inhibitors |
| 10/21/2004 | US20040208865 Immune complexes |
| 10/21/2004 | US20040208864 Methods of improving health-related quality of life in individuals with systemic lupus erythematosus |
| 10/21/2004 | US20040208857 Producing a donor-specific immunotolerance against transplanted tissue by administering embryonic stem cell-like cell lines (ECL) obtained from blastocysts and are transfected with genetic material of the donor, which codes for the major histocompatibility complex (MHC) haplotypes |
| 10/21/2004 | US20040208854 Methods and compositions for controlled release of bioactive compounds |
| 10/21/2004 | US20040208851 Immunization by inoculation of DNA transcription unit |
| 10/21/2004 | US20040208850 Antitumor agents; enhanced by administration of cytoxic T lymphocyte (CTLA-4) blocker and/or cytosine-guanosine (CpG) oligodeoxynucleotide immunomodulators |
| 10/21/2004 | CA2563393A1 Ml - iap peptides induce anti-melanoma cytotoxic t-cell response |
| 10/21/2004 | CA2528001A1 Lipid membrane structure containing anti-mt-mmp monoclonal antibody |
| 10/21/2004 | CA2522456A1 Nucleotide and cellular vaccine composition |
| 10/21/2004 | CA2521931A1 Use of hcv proteins |
| 10/21/2004 | CA2521856A1 Severe acute respiratory syndrome (sars) causing coronavirus |
| 10/21/2004 | CA2521602A1 Therapeutic composition for autoimmune conditions |
| 10/21/2004 | CA2521273A1 Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production |
| 10/21/2004 | CA2520867A1 Pulsatile transdermally administered antigens and adjuvants |
| 10/21/2004 | CA2501222A1 Antibody recognizing antigen |
| 10/21/2004 | CA2426280A1 Methods for preventing cattle reproductive diseases |
| 10/20/2004 | EP1469310A1 Diagnostic for scleroderma |
| 10/20/2004 | EP1469076A2 Recombinant PRRS proteins, diagnostic kits and vaccines containing said recombinant proteins |
| 10/20/2004 | EP1469072A2 Means and methods for diagnosing and treating affective disorders |
| 10/20/2004 | EP1468695A1 Methods and compositions useful for inhibition of angiogenesis |
| 10/20/2004 | EP1468682A1 Therapeutic combinations comprising amlodipine and atorvastatin |
| 10/20/2004 | EP1468614A1 Method of improving the growth or the efficiency of feed conversion of an animal and composition for use therein |
| 10/20/2004 | EP1468119A2 A METHOD OF DEVELOPING AN ANTI−PROTEIN AND REGULATION OF A CELLULAR FUNCTION BY ADMINISTERING AN EFFECTIVE AMOUNT OF THE ANTI−PROTEIN |
| 10/20/2004 | EP1468098A2 Method of inhibiting pathogenicity of infectious agents |
| 10/20/2004 | EP1468097A2 METHODS OF GENERATING MULTISPECIFIC, MULTIVALENT AGENTS FROM V sb H /sb AND V sb L /sb DOMAINS |
| 10/20/2004 | EP1468091A2 Transmembrane protein |
| 10/20/2004 | EP1468085A1 Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis |
| 10/20/2004 | EP1468080A1 INFECTIOUS cDNA CLONES OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND EXPRESSION VECTORS THEREOF |
| 10/20/2004 | EP1468022A1 Novel monoclonal antibody and nematode larval antigens |
| 10/20/2004 | EP1468019A2 Secreted protein |
| 10/20/2004 | EP1468018A2 Leptin proteins |
| 10/20/2004 | EP1468015A2 Novel compounds |
| 10/20/2004 | EP1468014A2 Compositions and methods for wt1 specific immunotherapy |
| 10/20/2004 | EP1468011A1 Biomolecule transduction motif sim-2-btm and the use thereof |
| 10/20/2004 | EP1468008A2 MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) PROMOTER POLYMORPHISM IN INFLAMMATORY DISEASE |
| 10/20/2004 | EP1467771A2 Mycobacterial vaccine |
| 10/20/2004 | EP1467759A2 Compositions and methods related to tim-3, a th1-specific cell surface molecule |
| 10/20/2004 | EP1467758A2 Methods for preparing immunoconjugates |
| 10/20/2004 | EP1467757A2 Use of antibodies against the muc18 antigen |
| 10/20/2004 | EP1467756A2 Methods for using anti-muc18 antibodies |
| 10/20/2004 | EP1467755A1 Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
| 10/20/2004 | EP1467754A1 Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus |
| 10/20/2004 | EP1467753A2 Recombinant herpesvirus of turkeys and use thereof |
| 10/20/2004 | EP1467752A1 HUMAN MAST CELL−EXPRESSED MEMBRANE PROTEINS |
| 10/20/2004 | EP1467751A2 Immunogenic cea |
| 10/20/2004 | EP1467720A2 Dna dosage forms |
| 10/20/2004 | EP1467711A2 Dna dosage forms |
| 10/20/2004 | EP1194450B1 Inactivated vaccine against feline calicivirus disease |
| 10/20/2004 | EP1181381B1 Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus |
| 10/20/2004 | EP1154790B1 Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs |
| 10/20/2004 | EP0983087B1 Multivalent vaccine composition with mixed carrier |
| 10/20/2004 | EP0959895B1 Peptides responsive to antibodies against a consensus peptide of the cs4-cfa/i family proteins |
| 10/20/2004 | EP0954332B1 Polynucleotide vaccine formula for treating dog diseases, particularly respiratory and digestive diseases |
| 10/20/2004 | EP0904107B1 Immunoglobin-like domains with increased half lives |
| 10/20/2004 | EP0886528B1 Use of coxiella bacteria to treat autoimmune disease |
| 10/20/2004 | EP0831860B1 Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
| 10/20/2004 | EP0771214B1 Treatment and prevention of helicobacter infection |
| 10/20/2004 | EP0734451B1 ENTEROTOXINS OF SHIGELLA FLEXNERI 2a |
| 10/20/2004 | EP0732939B1 Preparation and use of immunoconjugates comprising a VL-chain glycosylated at the Asn in position 18 |
| 10/20/2004 | EP0658113B1 Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof |
| 10/20/2004 | CN1539012A Electrodes coated with treating agent and uses thereof |
| 10/20/2004 | CN1538854A Mutant forms of cholera holotoxin as adjuvant |
| 10/20/2004 | CN1538853A T cell regulatory genes and methods of use thereof |
| 10/20/2004 | CN1171996C American pig reproduction and respiratory syndrome syndrome (PRRS) virus and its use |
| 10/20/2004 | CN1171900C Novel, ubiquitous potassium-channel proteins and genes for the same |
| 10/20/2004 | CN1171637C Vaccine against nepatitis B Birus and human papilloma virus |
| 10/20/2004 | CN1171636C Hepatitis B DNA vaccine |
| 10/20/2004 | CN1171630C LAK activity potentiator orginating in shiitake mushroom hyphae extract and LAK activty potentiating preparations containing the same |
| 10/19/2004 | US6806354 Methods and compositions for inducing autoimmunity in the treatment of cancers |
| 10/19/2004 | US6806352 Nucleotide sequences coding membrane proteins/pro-polypeptides; anticarcinogenic/antitumor agents |
| 10/19/2004 | US6806255 Compounds and methods for modulating adhesion molecule function |
| 10/19/2004 | US6806253 Therapeutic and preventive anti-bacterial vaccine complex |
| 10/19/2004 | US6806086 Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits |
| 10/19/2004 | US6806084 Comprises dna/lipid carrier complexes for transfection; for modulating the genotype and phenotype into two or more tissues following systemic administration; for gene therapy |
| 10/19/2004 | US6806065 Rickettsia felis outer membrane protein |
| 10/19/2004 | US6806055 Preparing viral vaccine; obtain glycoprotein, determine neutralizing epitope, generate vaccine associated with neutralizing epitope |
| 10/19/2004 | US6805870 Paramunity inducer based on combinations of poxvirus components, process to prepare it and its use as medicament |